Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.61 |
| ▸ | NOX1 | Q9Y5S8 | 3/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
| ▸ | ACHE | P22303 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7422398 | 0.82 | L3MBTL1 (0.69) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 | |
| Anthraquinone SCHEMBL22206675 | 0.82 | NOX1 (0.71) | L3MBTL1ALOX15ALDH1A1MAPTGAA | |
| SCHEMBL17085948 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 | |
| SCHEMBL19984763 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 | |
| SCHEMBL8878671 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 | |
| SCHEMBL1567426 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 | |
| SCHEMBL10669023 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 | |
| SCHEMBL7710864 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 | |
| SCHEMBL2113682 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 | |
| SCHEMBL31098239 | 0.81 | L3MBTL1 (0.68) | L3MBTL1ALOX15ALDH1A1MAPK10HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118460-A1 | PROCESS FOR THE SYNTHESIS OF QUETIAPINE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2011-05-19 | — | — | US | claimed |
| US-7902355-B2 | Condensation of 10H-dibenzo-[b,f][1,4]-thiazepin-11-one with a piperazine derivative in the presence of a titanium alkoxide catalyst; Titanium catalyst easier to handle, have low toxicity, not chlorinated, much less harmful for the environment | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2011-03-08 | — | — | US | claimed |
| EP-1856073-B1 | A PROCESS FOR THE PREPARATION OF AN 11-(4-SUBSTITUTED-I-PIPERAZINYL)DIBENZO[b,f][1,4]THIAZEPINE DERIVATIVE | UNION QUIMICO FARMA (ES) | 2010-05-12 | — | — | EP | claimed |
| US-20080171869-A1 | Process For The Preparation Of An 11-(4-Substituted-I- Piperazinyl)Dibenzo[B,F][1,4:rsqb; Thiazepine Derivative | UNION QUIMICO-FARMACEUTICA S.A. (ES) | 2008-07-17 | — | — | US | claimed |
| EP-1565448-A4 | METHOD OF PREPARING 10H-DIBENZO b,f 1,4 THIAZEPIN-11-ONE | SK HOLDINGS CO LTD (KR) | 2008-04-23 | — | — | EP | claimed |
| US-20070203336-A1 | Process for preparing dibenzothiazepine compounds | ASTRAZENECA UK LIMITED (GB) | 2007-08-30 | — | — | US | claimed |
| US-7214793-B2 | Method of preparing 10H-dibenzo[b,f][11,4]thiazepin-11-one | SK CORPORATION (KR) | 2007-05-08 | — | — | US | claimed |
| US-20070066589-A1 | Reacting dithiodisalicylic acid with 1-chloro-2-nitrobenzene in a basic aqueous solution; reducing the nitro group of the 2-(2-nitrophenylthio)benzoic acid formed with hydrogen gas, a solvent and a heterogeneous metal catalyst; and cyclizing the product in an organic solvent | SK BIOTEK CO., LTD. (KR) | 2007-03-22 | — | — | US | claimed |
| EP-1021190-B1 | Amid derivatives as growth hormone release promotors | KAKEN PHARMA CO LTD (JP) | 2006-11-08 | — | — | EP | claimed |
| EP-1565448-A2 | METHOD OF PREPARING 10H-DIBENZO b,f 1,4 THIAZEPIN-11-ONE | SK Corporation (KR) | 2005-08-24 | — | — | EP | claimed |
| WO-2004047722-A2 | METHOD OF PREPARING 10H-DIBENZO[b,f][1,4]THIAZEPIN-11-ONE | SK CORPORATION (KR) | 2004-06-10 | — | — | WO | claimed |
| CN-117402127-A | Preparation method of quetiapine intermediate | 苏州敬业医药化工有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-21 | — | — | US | disclosed |
| CN-106413402-B | Hepatitis b core protein allosteric modulators | 美国印第安纳大学研究和技术公司 | 2020-10-30 | — | — | CN | disclosed |
| US-4879288-A | Novel dibenzothiazepine antipsychotic | ICI AMERICAS INC. (US) | 1989-11-07 | — | — | US | disclosed |
| EP-0282236-A1 | Process for the preparation of a thiazepine compound | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-14 | — | — | EP | disclosed |
| US-4728735-A | LIPOXYGENASE INHIBITORS | MERCK & CO., INC. (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0240228-A1 | Thiazepine compounds | ICI AMERICAS INC. (US) | 1987-10-07 | — | — | EP | disclosed |
| US-4263207-A | ANTIALLERGENS | MERCK & CO., INC. (US) | 1981-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171869-A1 | Process For The Preparation Of An 11-(4-Substituted-I- Piperazinyl)Dibenzo[B,F][1,4:rsqb; Thiazepine Derivative | SDHB, SDHA, CYP2F1 | L3MBTL1 3398/4885ALOX15 1431/4885ALDH1A1 513/4885 |
| US-20070066589-A1 | Reacting dithiodisalicylic acid with 1-chloro-2-nitrobenzene in a basic aqueous solution; reducing the nitro group of the 2-(2-nitrophenylthio)benzoic acid formed with hydrogen gas, a solvent and a heterogeneous metal catalyst; and cyclizing the product in an organic solvent | PTGS1, PTGS2, CA2 | L3MBTL1 4573/4885ALOX15 63/4885ALDH1A1 754/4885 |
| US-20210017294-A9 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | L3MBTL1 2785/4885ALOX15 1292/4885ALDH1A1 2245/4885 |
| US-20110118460-A1 | PROCESS FOR THE SYNTHESIS OF QUETIAPINE | CYP4F11, MAOB, CYP2F1 | L3MBTL1 3838/4885ALOX15 873/4885ALDH1A1 1185/4885 |
| US-20070203336-A1 | Process for preparing dibenzothiazepine compounds | TST, ADH1C, ADH5 | L3MBTL1 4710/4885ALOX15 118/4885ALDH1A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.